Streetbeat News

Products Services

PLRX

Pliant Therapeutics, Inc. (NASDAQ:PLRX) announced positive data from a Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis and suspected moderate to severe liver fibrosis. The trial met its primary and secondary endpoints, showing that bexotegrast was well tolerated and its plasma concentrations increased with dose. The drug also showed statistically significant differences in reducing liver fibrosis markers at the 160 mg dose relative to placebo at Week 12. Interim data from the high-dose 320 mg cohort is expected in Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 11:33 am

ANTX

AN2 Therapeutics has signed a grant agreement to discover boron-based therapies for tuberculosis and malaria. The company's stock symbol is ANTX.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 11:15 am

AMWL

Health Gorilla and Amwell have announced a new lab capability within the Amwell Converge virtual care platform. This will allow providers on the platform to offer patients a more connected hybrid care experience through streamlined lab processes, enhanced digital diagnostic data capabilities, and access to a broader nationwide lab network.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 11:14 am

TLSA

Tiziana Life Sciences has initiated a Phase 2a trial of intranasal Foralumab for non-active secondary progressive multiple sclerosis. The trial aims to evaluate the safety and efficacy of the treatment.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 11:13 am

VIGL

Vigil Neuroscience has received a positive opinion from the European Medicines Agency on the orphan drug designation for VGL101, a treatment for ALSP. The company is currently evaluating VGL101 in a Phase 2 proof-of-concept trial. The drug was previously granted orphan drug designation by the U.S. FDA in July 2022.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 11:09 am

CLDX

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the Phase 1b study of barzolvolimab in patients with prurigo nodularis has been accepted as an oral presentation at the 12th World Congress on Itch in Miami. The study is a multi-center, randomized, double-blind, placebo-controlled trial designed to study barzolvolimab in patients with prurigo nodularis, a chronic skin disease.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 11:08 am

TECH

TMO

Bio-Techne has integrated its Maurice system with Thermo Scientific's Chromeleon Chromatography Data System. This integration will allow users to manage, analyze, and report protein characterization data.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 11:06 am

KPTI

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced that new selinexor data will be presented at the 2023 International Myeloma Society Annual Meeting in Athens, Greece. Additionally, findings from the SIENDO Study on patients with advanced or recurrent TP53 wild-type endometrial cancer will be featured in the 2023 European Society of Gynaecological Oncology Congress in Istanbul, Turkey.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 11:06 am

CYN

Cyngn Inc. (NASDAQ:CYN), a developer of AI-powered autonomous driving solutions, has begun deploying its DriveMod technology at a Fortune 100 Heavy Equipment Manufacturer's facility. The technology will automate repetitive driving tasks, increasing efficiency and safety. The deployment is part of the manufacturer's goal to increase automation and technology adoption. The companies are in talks to expand autonomous vehicle usage after this initial deployment.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 11:04 am

ONCY

Oncolytics Biotech has been awarded a $5M Therapeutic Accelerator Award from The Pancreatic Action Network for its work on pelareorep, an investigational immunotherapy treatment for cancer.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 11:04 am